| Author | Amico, K. Rivet | |
| Author | Mehrotra, Megha | |
| Author | Avelino-Silva, Vivian I. | |
| Author | McMahan, Vanessa | |
| Author | Veloso, Valdiléa G. | |
| Author | Anderson, Peter | |
| Author | Guanira, Juan | |
| Author | Grant, Robert | |
| Author | iPrEx Study Team | |
| Access date | 2018-10-10T16:09:34Z | |
| Available date | 2018-10-10T16:09:34Z | |
| Document date | 2016 | |
| Citation | AMICO, K. R. et al. Self-Reported Recent PrEP Dosing and Drug Detection in an Open Label PrEP Study. AIDS and Behavior, v. 20, p. 1535–1540, 2016 | pt_BR |
| ISSN | 1090-7165 | pt_BR |
| URI | https://www.arca.fiocruz.br/handle/icict/29493 | |
| Language | eng | pt_BR |
| Rights | restricted access | pt_BR |
| Title | Self-reported Recent PrEP Dosing and Drug Detection in an Open Label PrEP Study | pt_BR |
| Type | Article | |
| DOI | 10.1007/s10461-016-1360-7 | |
| Abstract | Monitoring adherence to pre-exposure prophylaxis (PrEP) is part of the recommended package for PrEP prescribing, yet ongoing concerns about how to do so confidently are exacerbated by gross discrepancies in reported and actual use in clinical trials. We evaluated concordance between reports of recent PrEP dosing collected via neutral interviewing and drug quantitation in the iPrEx open-label extension, where participants (n = 1172) had the choice to receive or not receive PrEP. Self-report of recent dosing (at least one PrEP dose in the past 3-day) was the most common report (84 % of participants), and among these 83 % did have quantifiable levels of drug. The vast majority of those reporting no doses in the past 3-day (16 % of the sample) did not have quantifiable levels of drug (82 %). Predictors of over-report of dosing included younger age and lower educational attainment. Monitoring recent PrEP use through neutral interviewing may be a productive approach for clinicians to consider in implementation of real-world PrEP. Strategies to capture longer term or prevention-effective PrEP use, particularly for younger cohorts, are needed. | pt_BR |
| Affilliation | Department of Health Behavior and Health Education, School of Public Health, University of Michigan, Ann Arbor, MI, USA. | pt_BR |
| Affilliation | Gladstone Institute of Virology and Immunology, University of California, San Francisco, CA, USA. | pt_BR |
| Affilliation | Universidade de São Paulo, Faculdade de Medicina, São Paulo, Brasil. | pt_BR |
| Affilliation | Gladstone Institute of Virology and Immunology, University of California, San Francisco, CA, USA. | pt_BR |
| Affilliation | Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil. | pt_BR |
| Affilliation | Department of Pharmaceutical Sciences, University of Colorado, Aurora, CO, USA. | pt_BR |
| Affilliation | Investigaciones Medicas en Salud, Lima, Peru. | pt_BR |
| Affilliation | Gladstone Institute of Virology and Immunology, University of California, San Francisco, CA, USA./ University of California, San Francisco, CA, USA. | pt_BR |
| Subject | PrEP adherence | pt_BR |
| Subject | Self-report | pt_BR |
| Subject | Drug levels | pt_BR |
| Subject | Open-label | pt_BR |
| Subject | Demonstration project | pt_BR |
| Subject | iPrEx | pt_BR |
| Subject | FTC/TDF | pt_BR |
| Embargo date | 2028-08-30 | |
